FDA Drug Safety Upgrades Coming; Medicare Bill Could Help Win Funding
This article was originally published in The Tan Sheet
Executive Summary
The Medicare prescription drug coverage legislation should help FDA make the case for additional funding for post-marketing surveillance, according to Center for Drug Evaluation & Research Acting Director Steven Galson, MD